Duraibabu Prathyusha 4
4 · SANGAMO THERAPEUTICS, INC · Filed Jan 26, 2026
Research Summary
AI-generated summary of this filing
Sangamo (SGMO) PFO Prathyusha Surrenders 36,676 Shares for Taxes
What Happened
Duraibabu Prathyusha, Principal Financial Officer of Sangamo Therapeutics (SGMO), had 36,676 shares surrendered to the company on January 22, 2026 to satisfy mandatory tax withholding related to vested restricted stock units (RSUs). The filing reports the disposition at $0.40/share for a total of $14,615 (issuer closing price used was $0.3985/share). This was a tax-withholding disposition (transaction code F), not an open-market sale or discretionary trade.
Key Details
- Transaction date: January 22, 2026; reported filing date: January 26, 2026 (timely within the 2-business-day Form 4 window).
- Reported price/value: 36,676 shares at $0.40/share = $14,615 (issuer closing price $0.3985/share used for withholding).
- Transaction code: F (shares surrendered for tax withholding).
- Shares owned after transaction: Not stated in the Form 4 provided.
- Footnote F1: Surrender was solely for mandatory tax withholding under the Issuer’s equity plan and is treated as a disposition for reporting—this was not a discretionary open-market sale.
- Footnote F2: Describes remaining RSU vesting schedule (includes 52,387 shares vested on Jan 22, 2026, plus other future vesting tranches from 2023 and 2025 grants) and notes vesting is subject to continued service and potential acceleration per the plan.
Context: This is a routine administrative tax-withholding transaction tied to RSU vesting. Such surrendering of shares to cover taxes is common and does not, by itself, indicate the insider’s view on the company.
Insider Transaction Report
- Tax Payment
Common Stock
[F1][F2]2026-01-22$0.40/sh−36,676$14,615→ 660,042 total
Footnotes (2)
- [F1]Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on January 22, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on January 22, 2026 of $0.3985/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
- [F2]Includes: (a) 52,387 shares from the January 22, 2026 vesting installment of the Reporting Person's January 22, 2024 RSU grant, (b) 5,010 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.